Canton Strategic Holdings, Inc., formerly Tharimmune, Inc., is advancing institutional blockchain adoption to drive the digitization of financial markets. In addition to driving value through activities on the Canton Network, the Company operates a Super Validator, ensuring safe and secure transactions across the Network. The Company also operates a clinical-stage biotech research and development arm. Its lead clinical asset, GV104, is being developed for a specific indication via a 505(b)2 pathway for respiratory and/or nervous system depression in military personnel and chemical incident responders who may encounter high-potency opioids. The expanded pipeline includes other indications for GV104 and GV023, a new approach to autoimmune diseases, as well as an early-stage multispecific biologic platform.
Back to dashboard
Company Information
About this company
Key people
Mark Wendland
Chairman of the Board, Chief Executive Officer
Mark Toomey
President
Jacob Asbury
Chief Financial Officer
Angela Dominy Radkowski
Chief Operating Officer
Pamela Lynn Carter
Independent Director
Sean P. Galvin
Independent Director
Clay Kahler
Independent Director
Rishi Nangalia
Independent Director
Jill E. Sommers
Independent Director
Click to see more
Key facts
- Shares in issue79.68m
- EPICCNTN
- ISINUS4327053090
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$170.52m
- Employees12
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.